The quest to overcome one of the biggest challenges in cancer treatment—resistance to therapy—is inextricably linked to Joseph R. Bertino, MD, AACR Fellow. Dr. Bertino, who died in October 2021 at age 91, helped define the mechanisms of action and resistance to one of the most important cancer chemotherapy agents, methotrexate. His ground-breaking work provided the first example of gene amplification as a mechanism of drug resistance. The AACR honored his legacy Saturday, April 9, by dedicating the Educational Session Drug Resistance: Challenges and Prospects to Dr. Bertino’s memory. The American Association for Cancer Research (AACR) Annual Meeting, was held April 8-13 in New Orleans. The drug resistance session and other meeting sessions can be viewed on the virtual platform by registered meeting participants through July 13, 2022. Registration can be done here. Over 19,000 scientists and physicians registered for this premier cancer conference, with ~80% (~15,200) attending in person and ~20% (~3,800) attending virtually. The AACR has over 50,000 members worldwide.
Login Or Register To Read Full Story